AWH vs. ICCC, OCX, ABIO, CDIO, TRIB, BMRA, VNRX, TKNO, GBS, and RPID
Should you be buying Aspira Women's Health stock or one of its competitors? The main competitors of Aspira Women's Health include ImmuCell (ICCC), OncoCyte (OCX), ARCA biopharma (ABIO), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), VolitionRx (VNRX), Alpha Teknova (TKNO), GBS (GBS), and Rapid Micro Biosystems (RPID). These companies are all part of the "medical" sector.
ImmuCell (NASDAQ:ICCC) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.
ImmuCell has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.
In the previous week, Aspira Women's Health had 4 more articles in the media than ImmuCell. MarketBeat recorded 10 mentions for Aspira Women's Health and 6 mentions for ImmuCell. Aspira Women's Health's average media sentiment score of 0.16 beat ImmuCell's score of -0.21 indicating that ImmuCell is being referred to more favorably in the media.
ImmuCell received 108 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 28.26% of users gave Aspira Women's Health an outperform vote.
13.5% of ImmuCell shares are held by institutional investors. Comparatively, 12.2% of Aspira Women's Health shares are held by institutional investors. 6.3% of ImmuCell shares are held by insiders. Comparatively, 4.3% of Aspira Women's Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
ImmuCell has a net margin of -18.31% compared to ImmuCell's net margin of -163.95%. Aspira Women's Health's return on equity of -15.21% beat ImmuCell's return on equity.
Aspira Women's Health has a consensus target price of $4.45, suggesting a potential upside of 67.29%. Given ImmuCell's higher possible upside, analysts plainly believe Aspira Women's Health is more favorable than ImmuCell.
ImmuCell has higher revenue and earnings than Aspira Women's Health. ImmuCell is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
Summary
ImmuCell beats Aspira Women's Health on 11 of the 17 factors compared between the two stocks.
Get Aspira Women's Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for AWH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AWH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aspira Women's Health Competitors List
Related Companies and Tools
